Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.

By: Jim Gallagher, senior managing editor

Retinal Physician June 18, 2026

Clinical Report: Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Overview

Early real-world experience with Encelto suggests a 36% reduction in photoreceptor loss and significant improvements in reading speed and retinal sensitivity.

Background

Macular telangiectasia type 2 (MacTel) is a chronic, progressive neurodegenerative condition affecting central vision, primarily in midlife patients. The approval of Encelto represents a new treatment option for this condition.

Data Highlights

Outcome	Reduction
Photoreceptor loss	36%
Monocular reading speed loss	68%
Retinal sensitivity loss	35%

Key Findings

Encelto demonstrated a 36% reduction in photoreceptor loss over 2 years.
Monocular reading speed loss was reduced by 68% compared to controls.
Retinal sensitivity loss decreased by approximately 35% with treatment.
Real-world surgical techniques have evolved to minimize complications.
Approximately 20% of patients experience mild delayed dark adaptation.

Clinical Implications

Patient selection is critical, with emphasis on identifying younger patients and those with specific structural evidence of disease progression.

Conclusion

The findings from clinical trials and early real-world experiences indicate that Encelto is a treatment option for patients with MacTel.

PentaVision

Retinal Physician